Mefloquine Tablets Rx
Generic Name and Formulations:
Mefloquine (as HCl) 250mg; scored tabs.
Various generic manufacturers
Indications for Mefloquine Tablets:
Prophylaxis of P. falciparum (including chloroquine-resistant strains) and P. vivax malaria. Treatment of mild to moderate acute malaria due to susceptible strains of P. falciparum or P. vivax.
Take with food and 8oz water. Prophylaxis: 250mg once weekly starting 1 week before departure, continuing during travel to endemic areas and for 4 weeks after return. Treatment: 1250mg as a single dose.
Give with food and water. May crush tab and mix in water. Prophylaxis: 3–5mg/kg once weekly starting 1 week before departure, continuing during travel to endemic areas and for 4 weeks after return. Treatment: ≤6months of age: contact manufacturer. ≥6months: 20–25mg/kg as single dose or as 2 doses 6–8 hours apart.
Quinine, quinidine, or related allergy. Not for prophylactic use in patients with psychiatric disorders or history of depression or seizures.
Do not use for life-threatening P. falciparum infection. After initial treatment for acute P. vivax infection, follow with an 8-aminoquinoline (eg, primaquine) to eliminate exoerythrocytic phase. Discontinue prophylactic therapy if unexplained CNS disturbances occur. Cardiac disease. Psychiatric disturbances. Seizure disorders. Hepatic impairment. Monitor liver, visual function in long-term use. Pregnancy (Cat.C); use adequate contraception. Nursing mothers: not recommended.
Do not use during or within 12 hours of quinine, quinidine, chloroquine (may cause seizures or ECG changes); caution with drugs that cause QTc prolongation (eg, β-blockers). Do not use halofantrine or ketoconazole during or within 15 weeks of last mefloquine dose. Caution with rifampin. May affect or be affected by CYP3A4 inhibitors or inducers, p-glycoprotein substrates. May antagonize antiepileptics. Complete live oral bacterial vaccinations (eg, typhoid) at least 3 days before 1st mefloquine dose. Monitor anticoagulants, antidiabetics, antiepileptics 2–3 weeks before departure.
Vomiting, dizziness, vertigo, syncope, extrasystoles, myalgias, fever, headache, chills, diarrhea, rash, abdominal pain, fatigue, anorexia, tinnitus; rare: seizures, cardiac arrest, encephalopathy, CNS/emotional disturbances.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma